Table 2.
Estimated clinical utility of clinical high risk psychometric instruments for psychosis prediction in various populations
| Sample | Psychosis risk | Positive test result | Negative test result |
|---|---|---|---|
| Unselected psychiatric adolescents (27) | 3.13% (12 mo.) | 3.13% | 0.29% |
| Subjects in contact with public treatment services (54) | 0.35% (lifetime) | 0.63% | <0.001% |
| Psychiatric patients in forensic units (55) | 74% (lifetime) | 83.38% | 20.39% |
| Primary care patients (56) | 0.045% (per year) | <0.001% | <0.001% |
| Prisoners (57) | 3.90% (lifetime) | 6.87% | 0.36% |
| Post-partum women (58) | 4% (12 mo.) | 7.04% | 0.37% |
| 22q11.2 deletion syndrome (59) | 16% (48 mo.) | 25.74% | 1.68% |
| Young adults at familial risk for psychosis (60) | 12% (30 mo.) | 19.88% | 1.21% |
| Users of high potency cannabis (61) | 24% (lifetime) | 36.49% | 2.76% |
| Military (62) | 0.014% (per year) | <0.001% | <0.001% |
| Black ethnic minority (63) | 1.45% (lifetime) | 2.60% | 0.13% |
| Refugees (64) | 3.3% (lifetime) | 5.84% | 0.31% |
| Epilepsy (65) | 5.6% (lifetime) | 9.74% | 0.53% |